Abstract
More than 60% of cleavage-stage and 50% of blastocyst-stage embryos are chromosomally abnormal. Morphological selection cannot discern most of these abnormalities, thus preimplantation genetic diagnosis has been used to screen for their presence. Conflicting results have been obtained using FISH and cleavage-stage biopsy, mostly owing to differences in methodology. When using appropriate preimplantation genetic diagnosis techniques, preimplantation genetic diagnosis significantly increases implantation rates and reduces spontaneous abortion rates in patients with advanced maternal age or recurrent pregnancy loss. Newer techniques such as comparative genome hybridization, array comparative genome hybridization and single-nucleotide polymorphism arrays can analyze all chromosome aneuploidies, and preliminary results indicate significant improvement on assisted reproductive technologies results, especially when coupled with blastocyst biopsy.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.